The stock decreased 0.29% or $0.27 during the last trading session, reaching $94.3. For the full year, analysts expect earnings to jump 10.49% yoy to $5.69. About 3.36M shares traded. Its quick ratio for most recent quarter is 1.50. Suntrust Banks Inc has 0.01% invested in Quest Diagnostics Inc (NYSE:DGX) for 24,186 shares. In general, if the indicator goes above -20, the stock may be considered overbought. BlackRock Inc. lifted its stake in shares of Quest Diagnostics by 2,638.3% in the first quarter. Also, CEO Stephen H. Rusckowski sold 53,933 shares of the stock in a transaction that occurred on Monday, September 11th. Parallel Advisors increased its position in Quest Diagnostics by 16.1% in the Q1. Baird Financial Group Inc. lifted its stake in shares of Quest Diagnostics by 4.2% in the 1st quarter.
COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was copied illegally and republished in violation of US and worldwide copyright legislation. Argus Research initiated Quest Diagnostics Inc (NYSE:DGX) on Friday, May 12 with “Hold” rating. Mondrian Investment Partners Ltd sold 3,001 shares as Bio (TECH)’s stock rose 4.48%. The shares were sold at an average price of $106.66, for a total value of $31,571.36. After a recent check, it is observed that the insiders for the firm now own 99.50% shares. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Deep diving into the technical levels for Ocwen Financial Corp (OCN), we note that the equity now has a 14-day Commodity Channel Index (CCI) of 163.24.
Investors may be searching for stocks that are undervalued. Quantbot Technology LP owns 57 shares for 0% of their portfolio. The disclosure for this sale can be found here. (NYSE:AXN) closed at $0.14 a share in the latest session and the stock value rose nearly -57.51% since the beginning of this year. Following the completion of the transaction, the director now directly owns 6,296 shares of the company’s stock, valued at $684,564.08. The stock of Quest Diagnostics Inc (NYSE:DGX) earned “Sector Perform” rating by RBC Capital Markets on Friday, October 23.
The stock has a market cap of $12.92B and the number of outstanding shares has been calculated 137.00M. Quest Diagnostics has a 52 week low of $79.12 and a 52 week high of $112.97. The firm has a 50-day moving average of $106.58 and a 200 day moving average of $105.42. Sandy Spring Commercial Bank stated it has 0% in Quest Diagnostics Inc (NYSE:DGX). After $1.02 actual EPS reported by BIO-TECHNE Corp for the previous quarter, Wall Street now forecasts -20.59% negative EPS growth. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. DGX has a current ratio of 1.60 compared to 1.50 for TMO.
Among 14 analysts covering Campbell Soup (NYSE:CPB), 1 have Buy rating, 5 Sell and 8 Hold. Stockholders of record on Tuesday, October 3rd will be paid a $0.45 dividend. (ABBV) in Focus: “Stock Moves 6.1% Higher” with publication date: “September 08, 2017.
DGX has been the discussion subject of Quite a few recent brokerage firm research. Zacks upgraded the stock to “Hold” rating in Tuesday, August 18 report. ValuEngine lifted Quest Diagnostics from a “hold” recommendation to a “buy” recommendation in a analysis report on Friday morning, Jun 2nd. BidaskClub cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, July 24th. As per Tuesday, July 25, the company rating was maintained by Canaccord Genuity. They noted that the move was a valuation call. Short shares increased 254,749 over that timeframe. Quest Diagnostics now has a average recommendation of “Hold” and an average price target of $111.09.
Quest Diagnostics Incorporated (DGX) stock’s current distance from 20-Day Simple Moving Average is -10.72% and moving -11.54% away from 50-Day Simple Moving Average while traded down -7.06% from 200-Day Simple Moving Average. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks, health plans, employers and accountable care organizations (ACOs).